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1 Veterinary Orthopedic and Sports Medicine, Annapolis Junction, MD, USA, 2 Las Vegas Veterinary Specialty Center,
Las Vegas, NV, USA
Objective: To quantitate key parameters of the platelet-rich plasma (PRP) product from
five commercial canine PRP systems in healthy, adult canines.
Materials andMethods: A prospective study was performed from January 2013 to April
2014. Five commercial systems were analyzed using 10 healthy dogs per system.1–5
Blood was obtained according to the manufacturer’s protocol for each system. The
mean baseline whole blood platelet, RBC, WBC, neutrophil, monocyte, and lymphocyte
concentrations were determined for each PRP system. All blood samples were processed
according to the manufacturer’s protocols. The mean PRP product platelet, RBC, WBC,
neutrophil, monocyte, and lymphocyte concentrations were determined for each PRP
system. These values were then compared to the mean baseline values. Comparisons
of mean whole blood and mean PRP product parameters were calculated using a paired
t-test with significance established at p=0.05.6
Results: Platelet concentration was significantly increased for System 1 (p=0.0088)
and System 3 (p<0.0001), and was significantly decreased for System 2 (p<0.0001).
All five systems significantly decreased the red blood cell concentration (p<0.0001
for each system comparison). Neutrophil concentration was significantly decreased for
System 2, System 3, and System 4 (p<0.0001 for each system comparison). Neutrophil
concentration was significantly increased for System 5 (p=0.0089).
Clinical Relevance: The systems with the highest platelet yield were System 1 and
System 3. System 3 increased platelet concentration while significantly reducing the RBC
and neutrophil concentrations. Further study is indicated to assess the efficacy of PRP
therapy in canines, the efficacy of canine PRP systems, and the clinical applications for
PRP therapy in dogs.
Keywords: platelet-rich plasma, autologous conditioned plasma, leukocyte-rich platelet-rich plasma, leukocyte-
poor platelet-rich plasma, platelet count
Abbreviations: ACP, autologous conditioned plasma; LP-PRP, leukocyte-poor platelet-rich plasma; LR-PRP, leukocyte-rich
platelet-rich plasma; PRP, platelet-rich plasma; RBC, red blood cell; WBC, white blood cell.
1SmartPReP®2 ACP+, Harvest Technologies, Corp, Plymouth, MA, USA.
2Arthrex ACP, Arthrex Orthobiologics, Naples, FL, USA.
3CRT Pure PRP, Canine Regenerative Therapies, Fort Meyers, FL, USA.
4ProTec PRP, Pulse Veterinary Technologies, LLC, Alpharetta, GA, USA.
5C-PET Canine Platelet Enhancement Therapy, Pall Corporation, Port Washington, NY, USA.
6Las Vegas Veterinary Specialty Center, Las Vegas, NV, USA.
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INTRODUCTION
Platelet-rich plasma (PRP) is an autogenous fluid concentrate
composed primarily of platelets and growth factors. Recent studies
have shown PRP to mediate healing by supplying growth factors,
cytokines, chemokines, and other bioactive compounds (1–7).
Initially, PRP’s first clinical applications were limited to dentistry
and maxillofacial surgery to improve bone healing. However,
PRP currently has much broader clinical applications, extending
to orthopedic surgery and sports medicine. Recent studies have
shown PRP to be efficacious in managing many different ortho-
pedic conditions, including osteoarthritis and soft tissue injuries
(3, 4, 7–31).
Platelets play roles in both hemostasis and wound healing.
Platelets contain granules that release growth factors to stimulate
other cells of the body to migrate to the area of trauma, thus
facilitating tissue healing. It is the growth factors contained within
the platelets that are of significance for tissue healing. These
growth factors include platelet-derived growth factor (PDGF),
transforming growth factor-β1 (TGF-β1), transforming growth
factor-β2 (TGF-β2), vascular endothelial growth factor (VEGF),
basic fibroblastic growth factor (bFGF), and epidermal growth
factor (EGF) (1–4, 6). Many of the growth factors found in PRP
have been shown to act either individually or synergistically to
enhance cellular migration and proliferation, angiogenesis, and
matrix deposition to promote tendon and wound healing, aid
in bone healing, and counteract the cartilage breakdown that is
associated with osteoarthritis (2–8, 10, 13, 19, 22, 26, 29, 31)
Thus, PRP has been used to manage many different orthope-
dic conditions. A number of studies have supported the use of
PRP for soft tissue healing (10, 11, 19–21, 24–27, 30). A recent
double-blinded, randomized controlled trial showed that patients
with patellar tendinopathy treated with PRP had greater function
and less pain than patients in the control group (11). Multiple
studies have also documented the use of PRP for management
of osteoarthritis (7, 8, 12–18, 22, 23). One recent prospective,
blinded, randomized trial showed a single dose of PRP to be
more effective than a placebo for improving function in humans
with knee osteoarthritis (22). Furthermore, recent studies have
also shown that platelets recruit, stimulate, and provide a scaffold
for stem cells, supporting its use with stem cells to stimulate
healing (27, 31–39). Hence, PRP has also been used in conjunction
with stem cell therapy to aid in cartilage, bone, and soft tissue
healing.
Multiple formulations of PRP have been developed and studied.
Previous studies in humans have reported that the ideal PRP prod-
uct should have anywhere from a four- to sevenfold increase in
platelets (2–4, 6). However, platelet concentration is not the only
important component of a PRP product. Inclusion or exclusion
of mononuclear cells, neutrophils, and red blood cells not only
define an autologous platelet product but have also been reported
to affect the clinical efficacy of the product and play major roles
affecting the inflammatory responses after PRP injection (2, 5,
10, 19–22, 40–44). In general, it is believed that red blood cells
and neutrophils should be reduced as they have an inflamma-
tory effect, while the effect of mononuclear cells remains largely
unknown (36, 40, 41, 45–48).
Multiple commercial PRP separation systems have been devel-
oped for both human and equine use. PRP products from dif-
ferent commercially available PRP separation systems often have
variations in their concentrations of platelets, WBC, and growth
factors (6, 43). Furthermore, while these systems may have been
previously validated for human and/or equine use, there is limited
research supporting their validation of a PRP system for canine
use. In fact, a recent study revealed that PRP systems validated
for human and/or equine use may not yield similar or consistent
results in the canine (44). Another recent study evaluated some of
the commercial canine PRP systems and also found inconsistent
results; however, this study failed to perform statistical analysis
and WBC differential on the PRP products (49). The purpose of
this studywas to compare key parameters of the PRPproduct from
five of the most commonly used commercial canine PRP systems
in healthy, adult canines.
MATERIALS AND METHODS
A prospective study involving two small animal surgery specialty
centers was performed from January 2013 to April 2014. In accor-
dance with AAALAC International Rules of Accreditation, this
study was performed with the approval of the VOSM Research
Committee and with owner consent. In this study, all dogs who
participated were client-owned dogs deemed healthy by a veteri-
narian.All clients volunteered their dog for the study andprovided
written consent as required by Veterinary Orthopedic and Sports
Medicine Group for every study participant. All dogs that par-
ticipated in the study were directly overseen by a veterinarian to
ensure no harm was incurred during study participation.
The following five commercial systems were prospectively ana-
lyzed and labeled as follows: System 1,1 System 2,2 System 3,3
System 4,4 and System 5.5 Data for Systems 1, 3, and 4 were
collected at Center 1,7 while data for Systems 2 and 5 were col-
lected at Center 2 (See footnote 6). Ten adult, healthy dogs with
no known previous or current medical problems were used for
each PRP system. Two of the canines were used for both System
3 and System 4. In this case, the blood samples were collected on
separate days, 30 days apart from each other. One investigator was
appointed at each center to perform blood collection and sample
processing. The required volume of blood was then obtained from
each dog according to the manufacturer’s protocol and specifi-
cations for each PRP system (Table 1). For System 1, System 2,
System 3, and System 5, all blood samples were obtained from the
jugular vein using an 18-gage-butterfly needle. All blood samples
for System 4 were collected from the jugular vein; however, Sys-
tem 4 required the use of a 21-gage-butterfly needle vacutainer
as blood was collected directly into the sodium citrate tubes
provided by the manufacturer for processing. A baseline blood
WBC differential, RBC concentration, and platelet concentration
were obtained on all dogs using an in-house hematology analyzer
that had been calibrated according to manufacturer standards.8
7Veterinary Orthopedic and Sports Medicine Group, Annapolis Junction,
MD, USA.
8Idexx LaserCyte Hematology Analyzer, Idexx Laboratories, Westbrook, ME, USA.
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TABLE 1 | PRP system protocols summary.
System Centrifugation or
filtration
Volume of
blood required
Anticoagulant Volume of
anticoagulant
Size of
syringe used
PRP product
volume
1 Centrifugation 50mL ACD-A 10mL 60mL 10mL
2 Centrifugation 16mL ACD-A 1.5mL 20mL 4–7mL
3 Centrifugation 50mL ACD-A 10mL 60mL 4mL
4 Centrifugation 9mL Sodium citrate 1mL n/a 4–5mL
5 Filtration 55mL ACD-A 5mL 60mL 6–8mL
The following five commercial systems were prospectively analyzed and labeled as follows: System 1, System 2, System 3, System 4, and System 5. Blood was then obtained from
each dog according to the manufacturer’s protocol and specifications for each PRP system. This table summarizes the main characteristics of each system’s protocol.
FIGURE 1 | Comparison of mean whole blood and mean PRP product platelet concentrations between five commercial PRP systems. An asterisk (*)
indicates a statistically significant difference between the mean whole blood and mean PRP product for that PRP system. Bars represent mean95% CI (n=10).
The mean baseline whole blood platelet, RBC, WBC, neutrophil,
monocyte, and lymphocyte concentrations were determined for
each PRP system. Baseline concentrations were obtained imme-
diately following blood draw for all dogs. All blood samples were
processed immediately following blood draw according to the
protocols established by the manufacturer. PRP product con-
centrations were obtained immediately following processing. The
platelet, RBC, WBC, neutrophil, monocyte, and lymphocyte con-
centrations were obtained for all processed samples. The mean
PRP product platelet, RBC, WBC, neutrophil, monocyte, and
lymphocyte concentrations were determined for each PRP sys-
tem. The D’Agostino & Pearson Omnibus normality test was
performed on the differences between PRP and Whole Blood for
each data set with significance established at p= 0.01. All data sets
were found to be normally distributed. Data were then analyzed
using a paired t-test. These values were analyzed using statistical
software.9 Significance was established at p= 0.05.
RESULTS
Blood was obtained from a total of 48 different healthy,
adult canines. The following breeds were represented: Labrador
Retriever (n= 7), Border Collie (n= 5), German Shepherd Dog
9GraphPad Prism 6, GraphPad Software Inc, La Jolla, CA, USA.
(n= 4), Golden Retriever (n= 4), Rottweiler (n= 3), Boxer Dog
(n= 2), Doberman (n= 2), English Bulldog (n= 2), Pit Bull Ter-
rier (n= 2), American Bulldog (n= 1), American Staffordshire
Terrier (n= 1), Belgian Malinois (n= 1), Collie (n= 1), French
Bulldog (n= 1), Great Dane (n= 1), Keeshond (n= 1), Mastiff
(n= 1), Newfoundland (n= 1), Standard Poodle (n= 1), Vizsla
(n= 1), and mixed canine (n= 6). There were 6 intact males,
17 neutered males, 8 intact females, and 17 spayed females. The
mean weight was 31.6 kg (range 11.3–55.5 kg). The mean age was
6.2 years old (range 1–13 years old).
Platelet Concentration
A statistically significant difference was found between the mean
whole blood and mean PRP product platelet concentrations of
System 1, System 2, and System 3 (Figure 1). Mean platelet con-
centration was significantly increased for System 1 (p= 0.0088),
which was a 219% increase, and for System 3 (p< 0.0001), a 550%
increase. Mean platelet concentration was significantly decreased
for System 2 (p< 0.0001), which was a 91% decrease. There was
no statistically significant change in mean platelet concentration
for System 4 (p= 0.6107) and System 5 (p= 0.0897).
RBC Concentration
A statistically significant difference was found between the mean
whole blood and mean PRP product RBC concentrations of all
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five PRP systems (Figure 2). Mean RBC concentration was signif-
icantly decreased for System 1 (p< 0.0001), System 2 (p< 0.0001),
System 3 (p< 0.0001), System 4 (p< 0.0001), and System 5
(p< 0.0001). System 2 was found to have the greatest decrease in
RBC concentration (98%), followed by System 4 (96%), System 3
(95%), System 1 (85%), and System 5 (37%).
WBC Concentration
A statistically significant difference was found between the mean
whole blood and mean PRP product WBC concentrations of
System 2, System 4, and System 5 (Figure 3). Mean WBC con-
centration was significantly decreased for System 2 (p< 0.0001)
and System 4 (p< 0.0001), an 89% decrease for both systems.
Mean WBC concentration was significantly increased for System
5 (p= 0.0005), which is a 110% increase. There was no statistically
significant change in mean WBC concentration for System 1
(p= 0.2161) and System 3 (p= 0.3439).
Neutrophil Concentration
A statistically significant difference was found between the mean
whole blood and mean PRP product neutrophil concentrations
of System 2, System 3, System 4, and System 5 (Figure 4). Mean
neutrophil concentration was significantly decreased for System
2 (p< 0.0001), System 3 (p< 0.0001), and System 4 (p< 0.0001).
System 2 yielded a 90% decrease, System 3 yielded an 85%
decrease, and System 4 yielded a 98% decrease in mean neu-
trophil concentration compared to mean whole blood values.
Mean neutrophil concentration was significantly increased for
System 5 (p= 0.0089), a 59% increase. There was no statistically
significant change in mean neutrophil concentration for System 1
(p= 0.9300).
Monocyte Concentration
A statistically significant difference was found between the mean
whole blood and mean PRP product monocyte concentrations of
System 2, System 4, and System 5 (Figure 5).Meanmonocyte con-
centration was significantly decreased for System 2 (p= 0.0064),
which was a 62% decrease, and for System 4 (p< 0.0001), a
79% decrease. Mean monocyte concentration was significantly
increased for System5 (p= 0.0032), a 114% increase. Therewas no
statistically significant change in mean neutrophil concentration
for System 1 (p= 0.1245) and System 3 (p= 0.7759).
FIGURE 2 | Comparison of mean whole blood and mean PRP product RBC concentrations between five commercial PRP systems. An asterisk (*)
indicates a statistically significant difference between the mean whole blood and mean PRP product for that PRP system. Bars represent mean95% CI (n=10).
FIGURE 3 | Comparison of mean whole blood and mean PRP product WBC concentrations between five commercial PRP systems. An asterisk (*)
indicates a statistically significant difference between the mean whole blood and mean PRP product for that PRP system. Bars represent mean95% CI (n=10).
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FIGURE 4 | Comparison of mean whole blood and mean PRP product neutrophil concentrations between five commercial PRP systems. An asterisk (*)
indicates a statistically significant difference between the mean whole blood and mean PRP product for that PRP system. Bars represent mean95% CI (n=10).
FIGURE 5 | Comparison of mean whole blood and mean PRP product monocyte concentrations between five commercial PRP systems. An asterisk (*)
indicates a statistically significant difference between the mean whole blood and mean PRP product for that PRP system. Bars represent mean95% CI (n=10).
Lymphocyte Concentration
A statistically significant difference was found between the mean
whole blood and mean PRP product lymphocyte concentrations
of all five PRP systems (Figure 6). Mean lymphocyte concentra-
tionwas significantly decreased for System2 (p= 0.0004), which is
a 74% decrease, and System 4 (p= 0.0004), a 67% decrease. Mean
lymphocyte concentration was significantly increased for System
1 (p= 0.0494), System 3 (p= 0.0260), and System 5 (p= 0.0013).
System 1 yielded a 191% increase, System 3 a 220% increase,
and System 5 a 267% increase in mean lymphocyte concentration
compared to mean whole blood values.
DISCUSSION
Platelet-rich plasma concentration results varied among systems.
The systems with the highest platelet yield were System 1 and
System 3. However, while System 1 yielded a 219% mean increase
in platelets and 85% decrease in RBC from baseline, this system
failed to reduce neutrophil concentrations. System 3 yields a 550%
mean increase in platelets while removing >95% of the RBC and
85% of neutrophils.
Multiple formulations of PRP have been developed and studied.
Previous studies in humans have reported that the ideal PRP prod-
uct should have anywhere from a four- to sevenfold increase in
platelets (2–4, 6). However, platelet concentration is not the only
important component of a PRP product. Inclusion or exclusion
of mononuclear cells, neutrophils, and red blood cells not only
define an autologous platelet product, but have also been reported
to affect the clinical efficacy of the product and play major roles
affecting the inflammatory responses after PRP injection (2, 5, 10,
19–22, 40–44). In this study, the systems with the highest platelet
yield were System 1 and System 3.
Reducing RBC concentration is thought to be important when
developing the ideal PRP product (40). A recent study revealed an
increased RBC concentration in PRP increases the concentrations
of unwanted inflammatory mediators, specifically IL-1 and TGF-
α. This study also showed that synoviocytes treatedwithRBCcon-
centrate demonstrated significantlymore synoviocyte death when
compared with leukocyte-rich PRP (LR-PRP), leukocyte-poor
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FIGURE 6 | Comparison of mean whole blood and mean PRP product lymphocyte concentrations between five commercial PRP systems. An asterisk
(*) indicates a statistically significant difference between the mean whole blood and mean PRP product for that PRP system. Bars represent mean95% CI (n= 10).
PRP (LP-PRP), and phosphate-buffered saline (PBS) (40). In this
study, all five canine PRP systems significantly decreased the RBC
concentration.
The effect of leukocyte concentration in PRP products has also
been investigated. Both LR-PRP and LP-PRP have been studied
and compared. Recent studies have shown LR-PRP is associated
with increased pro-inflammatory mediators, including IL-1β, IL-
6, IL-8 IFN-γ, and TNF-α (1, 2, 5, 10, 40, 41). Increased leukocytes
in PRP are also associated with more metalloproteinase (MMP-
3 and MMP-13) gene expression and less cartilage oligomeric
matrix protein (COMP) and decorin gene expression (10, 36,
45). These potentially deleterious effects are largely attributed to
the presence of neutrophils. Additionally, an increased concen-
tration of neutrophils in PRP is also positively correlated with
an increased MMP-9 concentration which degrades collagen and
other extracellular matrix molecules (20, 36, 41, 45). One recent
study has shown LR-PRP causes significantly more synoviocyte
death when compared with LP-PRP and PBS (40). Thus, LP-PRP
has been thought to be more beneficial than LR-PRP in maintain-
ing tendon homeostasis and counteract inflammation associated
with osteoarthritis (10, 19, 20, 40, 45). Of the systems with the
highest platelet yield (System 1 and System 3), System 1 failed
to reduce WBC concentration and neutrophil concentrations,
while System 3 removed greater than 19% of WBC and 85% of
neutrophils.
While an increased neutrophil concentration in PRP is known
to have negative effects, the effect of monocytes and lymphocytes
remains largely unknown. There was great variation in this study
of monocyte and lymphocyte concentrations in the final PRP
product. Recent studies suggest that monocytes are associated
with an increase in cellularmetabolismand collagen production in
fibroblasts and a decrease in release of anti-angiogenic cytokines
interferon-γ and IL-12 (47, 48). Platelets have also been shown to
activate peripheral bloodmononuclear cells (lymphocytes, mono-
cytes, and macrophages) to help stimulate collagen production,
which is believed to be mediated by an increase in IL-6 expression
(47, 48). However, the role of monocytes and lymphocytes in PRP
therapy remains unclear and further investigation is warranted.
When compared to the previous study evaluating platelet
concentration of PRP products from various canine commer-
cial systems, our study found similar results (49). Three of the
commercial systems were tested in both studies. PRP product
platelet concentrations and total WBC concentrations were sim-
ilar between both studies. However, the previous study failed to
performWBCdifferentiation on the PRP products, so no compar-
isons can bemade regarding neutrophil, lymphocyte, ormonocyte
concentrations.
Limitations of this study include small sample size and limi-
tations inherent to its design. Different dogs were used for each
PRP system, and while all dogs were confirmed to be healthy,
one cannot assume that the dogs used are representative of the
entire canine population. Ideally, the same dog would be used for
all systems and all blood samples would be drawn at the same
time to eliminate variation in hematological composition. We
attribute the variation in results to this as well as inherent patient
factors. However, it was not possible to use the same dogs for
simultaneous sample collection and processing as the study was
conducted at two separate centers. Furthermore, it was also not
feasible to obtain the large blood sample required for all systems
to be tested simultaneously.
The goal of this study was to compare key parameters of the
PRP product from five commercial canine PRP systems in healthy,
adult canines. No claims regarding the efficacy of PRP therapy
in canines or the efficacy of the PRP formulations evaluated can
be deduced from this study. Further study is indicated to assess
the concentrations of growth factors and cytokines in the com-
mercial canine PRP products and to determine the concentration
of platelets and growth factors required for therapeutic effect.
Further study is also needed to evaluate the efficacy of PRP therapy
and further define its clinical applications in canines.
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